vs
FrontView REIT, Inc.（FVR）与SUTRO BIOPHARMA, INC.（STRO）财务数据对比。点击上方公司名可切换其他公司
FrontView REIT, Inc.的季度营收约是SUTRO BIOPHARMA, INC.的1.4倍（$16.5M vs $11.6M）
Sutro Biopharma是一家上市生物科技公司，总部位于加州南旧金山，专注于临床阶段药物的研发、开发与生产。公司依托自主专有的无细胞蛋白质合成平台，结合蛋白质工程与理性设计技术开发肿瘤治疗药物。公司2003年成立时名为Fundamental Applied Biology，2009年改用现名。
FVR vs STRO — 直观对比
营收规模更大
FVR
是对方的1.4倍
$11.6M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.5M | $11.6M |
| 净利润 | $-4.1M | — |
| 毛利率 | — | — |
| 营业利润率 | — | — |
| 净利率 | -24.9% | — |
| 营收同比 | — | -21.4% |
| 净利润同比 | — | 35.4% |
| 每股收益（稀释后） | $-0.19 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FVRSTRO
| Q4 25 | $16.5M | $11.6M | ||
| Q3 25 | $16.8M | $9.7M | ||
| Q2 25 | $17.6M | $63.7M | ||
| Q1 25 | $16.2M | $17.4M | ||
| Q4 24 | — | $14.8M | ||
| Q3 24 | $14.5M | $8.5M | ||
| Q2 24 | — | $25.7M | ||
| Q1 24 | — | $13.0M |
净利润FVRSTRO
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $4.0M | $-56.9M | ||
| Q2 25 | $-2.9M | $-11.5M | ||
| Q1 25 | $-833.0K | $-76.0M | ||
| Q4 24 | — | $-72.4M | ||
| Q3 24 | $-2.4M | $-48.8M | ||
| Q2 24 | — | $-48.0M | ||
| Q1 24 | — | $-58.2M |
营业利润率FVRSTRO
| Q4 25 | — | — | ||
| Q3 25 | — | -499.9% | ||
| Q2 25 | — | -5.2% | ||
| Q1 25 | — | -393.8% | ||
| Q4 24 | — | -440.7% | ||
| Q3 24 | — | -797.2% | ||
| Q2 24 | — | -189.4% | ||
| Q1 24 | — | -435.0% |
净利率FVRSTRO
| Q4 25 | -24.9% | — | ||
| Q3 25 | 23.9% | -586.6% | ||
| Q2 25 | -16.5% | -18.0% | ||
| Q1 25 | -5.1% | -436.6% | ||
| Q4 24 | — | -489.2% | ||
| Q3 24 | -16.7% | -572.6% | ||
| Q2 24 | — | -186.8% | ||
| Q1 24 | — | -447.5% |
每股收益（稀释后）FVRSTRO
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $0.19 | $-0.67 | ||
| Q2 25 | $-0.16 | $-0.14 | ||
| Q1 25 | $-0.06 | $-0.91 | ||
| Q4 24 | — | $-27.63 | ||
| Q3 24 | — | $-0.59 | ||
| Q2 24 | — | $-0.59 | ||
| Q1 24 | — | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $13.5M | $141.4M |
| 总债务越低越好 | $314.3M | — |
| 股东权益账面价值 | $391.2M | $-132.5M |
| 总资产 | $854.4M | $173.8M |
| 负债/权益比越低杠杆越低 | 0.80× | — |
8季度趋势，按日历期对齐
现金及短期投资FVRSTRO
| Q4 25 | $13.5M | $141.4M | ||
| Q3 25 | $19.6M | $167.6M | ||
| Q2 25 | $8.4M | $205.1M | ||
| Q1 25 | $3.3M | $249.0M | ||
| Q4 24 | — | $316.9M | ||
| Q3 24 | — | $388.3M | ||
| Q2 24 | — | $375.6M | ||
| Q1 24 | — | $267.6M |
总债务FVRSTRO
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FVRSTRO
| Q4 25 | $391.2M | $-132.5M | ||
| Q3 25 | $385.2M | $-87.3M | ||
| Q2 25 | $369.9M | $-32.1M | ||
| Q1 25 | $324.7M | $-25.8M | ||
| Q4 24 | — | $44.6M | ||
| Q3 24 | $1.0K | $111.2M | ||
| Q2 24 | — | $152.2M | ||
| Q1 24 | — | $98.0M |
总资产FVRSTRO
| Q4 25 | $854.4M | $173.8M | ||
| Q3 25 | $846.8M | $209.7M | ||
| Q2 25 | $856.5M | $262.4M | ||
| Q1 25 | $860.8M | $321.4M | ||
| Q4 24 | — | $387.2M | ||
| Q3 24 | $1.0K | $451.8M | ||
| Q2 24 | — | $489.0M | ||
| Q1 24 | — | $403.4M |
负债/权益比FVRSTRO
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $42.1M | $-177.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FVRSTRO
| Q4 25 | $42.1M | $-177.2M | ||
| Q3 25 | $8.3M | $-38.2M | ||
| Q2 25 | $9.3M | $-44.7M | ||
| Q1 25 | $8.1M | $-67.9M | ||
| Q4 24 | — | $-71.7M | ||
| Q3 24 | — | $-64.5M | ||
| Q2 24 | — | $9.5M | ||
| Q1 24 | — | $-64.7M |
现金转化率FVRSTRO
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
